Validation experiment designed to validate causal mechanisms targeting NTN1 in endometrial carcinoma mouse model. Primary outcome: therapeutic efficacy comparison
Preclinical evaluation of combination therapy using NP137 with standard-of-care chemotherapy (carboplatin-paclitaxel) in an endometrial carcinoma mouse model. Given the importance of EMT in resistance to current standards of care, this experiment tested whether combining netrin-1 blockade with conventional chemotherapy could improve therapeutic outcomes. The study demonstrated that the combination of NP137 with carboplatin-paclitaxel outperformed carboplatin-paclitaxel alone, suggesting that netrin-1 blockade could overcome chemotherapy resistance mediated by EMT mechanisms.
Combination treatment with NP137 plus carboplatin-paclitaxel versus carboplatin-paclitaxel alone
Superior efficacy of combination therapy
Improved tumor response with combination compared to chemotherapy alone
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.